<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Lentiviral-Vectors on Bioecon</title><link>https://en.bioecon.ru/technologies/lentiviral-vectors/</link><description>Recent content in Lentiviral-Vectors on Bioecon</description><generator>Hugo</generator><language>en-US</language><lastBuildDate>Thu, 23 Jul 2026 23:05:33 +0700</lastBuildDate><atom:link href="https://en.bioecon.ru/technologies/lentiviral-vectors/index.xml" rel="self" type="application/rss+xml"/><item><title>In-vivo gene therapy: AAV and lentiviral vectors</title><link>https://en.bioecon.ru/technology/gene-therapy-in-vivo-aav-lentiviral/</link><pubDate>Thu, 23 Jul 2026 00:00:00 +0000</pubDate><guid>https://en.bioecon.ru/technology/gene-therapy-in-vivo-aav-lentiviral/</guid><description>One-time, potentially curative genetic medicines delivered by engineered adeno-associated and lentiviral vectors — eight FDA-approved in-vivo products since 2017, from Luxturna to Beqvez, now a multi-billion-dollar clinical reality alongside honest commercial retrenchments.</description></item></channel></rss>